This test is most useful if any of these apply to you.
Your gut bacteria do not just digest food. They also produce small molecules that can travel through your bloodstream and reach your brain. HPHPA (3-(3-hydroxyphenyl)-3-hydroxypropionic acid) is one of those molecules, and it appears in your urine when certain bacteria, mostly from the Clostridia family, are unusually active in your intestines.
This test is most interesting if you want to look beyond a standard stool culture and ask what your gut microbes are actually making. It is an exploratory research marker, not a diagnostic test. There are no standardized clinical cutoffs, and a single reading cannot diagnose a disease on its own. What it can do is give you a window into a specific microbial activity that routine labs do not measure.
HPHPA is an unusual byproduct of phenylalanine, a protein building block. Several anaerobic Clostridium species in your gut convert phenylalanine into HPHPA through an intermediate called m-tyrosine, and HPHPA then passes into your urine. Your own cells do not make HPHPA in meaningful amounts, so when levels are high, the bacteria are the likely source.
HPHPA is thought to be a downstream product of m-tyrosine, a non-standard chemical cousin of dietary tyrosine. In animal studies, m-tyrosine can lower the brain's supply of catecholamines (chemical messengers like dopamine and norepinephrine that affect mood, focus, and motivation) as well as serotonin. This is the proposed reason researchers became interested in HPHPA as a gut-brain signal in the first place.
In the foundational study of this marker, children with autism had higher urinary HPHPA than age- and sex-matched controls. That finding was based on a small observational sample. A later replication in 62 children with autism and 62 matched controls also found significantly elevated HPHPA in the autism group, with reasonable separation between groups on statistical testing. Even so, HPHPA is not used as a stand-alone diagnostic test. It is best understood as a possible signal that a Clostridia-driven gut process may be active in some, but not all, children on the spectrum.
If you are exploring this marker in the context of autism, treat it as one piece of a larger picture. Elevated levels suggest a microbial pattern worth investigating further, not a diagnosis or a guarantee that addressing the bacteria will change behavior.
The most dramatic single finding in the HPHPA literature comes from a case report. A patient with acute schizophrenia had urinary HPHPA at roughly 300 times the median value seen in normal adults. After oral vancomycin, an antibiotic that targets gut Clostridia, HPHPA fell sharply and the psychosis went into remission.
This is a single case, not a clinical trial, and it should not be read as proof that gut bacteria cause psychosis or that antibiotics treat schizophrenia. What it does suggest is that when HPHPA is extremely elevated in someone with neuropsychiatric symptoms, the gut microbiome may be a legitimate part of the workup, not just an afterthought.
An adult with recurrent Clostridium difficile diarrhea also showed high urinary HPHPA in the same case series. This is consistent with the proposed biology: when Clostridia species are overgrowing in the gut, more of their phenylalanine-derived byproducts spill into urine. The marker does not distinguish between C. difficile specifically and other Clostridia species, so a high reading is a general flag, not a species identification.
In a metabolomics study of 43 people with pulmonary arterial hypertension (a form of high blood pressure in the arteries of the lungs) and 37 controls, HPHPA was one of eight blood and urine molecules combined into a diagnostic model. The full panel distinguished patients from controls with 91% accuracy. HPHPA on its own was not the discriminating factor, and the direction of change was not isolated. The signal is real but indirect.
HPHPA reflects microbial activity in your gut on a given day. Your microbiome shifts in response to diet, antibiotics, illness, and stress. A single number tells you what your bacteria were doing in the hours before you collected the sample. It does not tell you what they will be doing next month.
Because this is an exploratory marker without standardized cutoffs, the most useful information comes from tracking your own trend. Get a baseline reading. If you make a change that should affect your gut microbiome, such as starting a probiotic, changing your diet, or completing an antibiotic course, retest in 3 to 6 months to see whether your number moved. After that, annual checks make sense if this marker is part of how you monitor gut health.
A single high reading on a research-grade marker like this one should not drive a major clinical decision on its own. A repeat measurement that confirms the same pattern, combined with stool testing and your symptoms, carries far more weight than any one number.
If your HPHPA comes back markedly elevated, the next step is not to treat the number. It is to look at the rest of the picture. The most useful companion tests are stool-based: a comprehensive stool analysis that quantifies Clostridia species, a separate C. difficile assay if you have had recurrent diarrhea, and a broader organic acids panel that places HPHPA alongside other microbial byproducts.
If your reading is elevated and you have neuropsychiatric symptoms, gastrointestinal complaints, or a child on the autism spectrum with regression after antibiotics, the result is worth raising with a gastroenterologist or a clinician familiar with gut-brain medicine. Confirmatory stool testing and a careful look at recent antibiotic and dietary history come before any intervention. An isolated high HPHPA in someone without symptoms is a finding to track, not to act on aggressively.
Evidence-backed interventions that affect your HPHPA level
HPHPA is best interpreted alongside these tests.
HPHPA is included in these pre-built panels.